Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)

Journal of Clinical Investigation

Volumn 111, Issue 3, 2003, Pages 409-418

  Herold, Kevan C ^a,d   Burton, Joshua B ^a   Francois, Fleur ^b   Poumian Ruiz, Ena ^a   Glandt, Mariela ^a   Bluestone, Jeffrey A ^c  

^a NewYork Presbyterian Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 5; MONOCLONAL ANTIBODY OKT3 GAMMA1[ALANYLALANINE]; OKT 3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0037314237     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16090     Document Type: Article

References (60)

1. Staruch, M.J., Sigal, N.H., and Dumont, F.J. 1991. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. Int. J. Immunopharmacol. 13:677-685.
2. Sigal, N.H., and Dumont, F.J. 1992. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol. 10:519-560.
3. Kottaridis, P.D., et al. 2000. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 96:2419-2425.
4. Pangalis, G.A., et al. 2001. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med. Oncol. 18:99-107.
5. Li, X.C., et al. 2001. T cell death and transplantation tolerance. Immunity. 14:407-416.
6. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:737-742.
7. Salomon, B., and Bluestone, J.A. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225-252.
8. Herbelin, A., et al. 1998. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J. Immunol. 161:2620-2628.
9. Chatenoud, L., et al. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA. 91:123-127.
10. Herold, K.C., et al. 1992. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes. 41:385-391.
11. Chatenoud, L., Primo, J., and Bach, J.F. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158:2947-2954.
12. Bach, J.F., and Chatenoud, L. 2001. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19:131-161.
13. Chatenoud, L., and Bach, J.F. 1993. Anti-CD3 antibodies. Immunol. Ser. 59:175-191.
14. Chatenoud, L. 1994. Use of CD3 antibodies in transplantation and autoimmune diseases. Transplant Proc. 26:3191-3193.
15. Smith, S.L. 1996. Ten years of Otthoclone OKT3 (muromonab-CD3): a review. J. Transpl. Coord. 6:109-119.
16. Takahashi, K. 1995. Muromonab CD3 (Orthoclone OKT3). J. Toxicol. Sci. 20:483-484.
17. Chatenoud, L., Ferran, C., and Bach, J.F. 1991. The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation. Curr. Top. Microbiol. Immunol. 174:121-134.
18. Chatenoud, L. 1993. Humoral immune response against OKT3. Transplant Proc. 25:68-73.
19. Chatenoud, L. 1993. OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc. 25:47-51.
20. Woodle, E.S., et al. 1991. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc. 23:81-82.
21. Alegre, M.L., et al. 1992. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 148:3461-3468.
22. Woodle, E.S., et al. 1998. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc. 30:1369-1370.
23. Woodle, E.S., Hussein, S., and Bluestone, J.A. 1996. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells. Transplantation. 61:798-803.
24. Woodle, E.S., et al. 1999. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 68:608-616.
25. Smith, J.A., et al. 1997. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185:1413-1422.
26. Smith, J.A., Tang, Q., and Bluestone, J.A. 1998. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J. Immunol. 160:4841-4849.
27. Herold, K.C., et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:1692-1698.
28. Rabin, R.L., et al. 1999. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J. Immunol. 162:3840-3850.
29. Kukreja, A., et al. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109:131-140. doi:10.1172/JCI200213605.
30. Shevach, E.M. 2000. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18:423-449.
31. Xu, D., et al. 2000. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 200:16-26.
32. Alegre, M.L., et al. 1994. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 57:1537-1543.
33. Toellner, K.M., et al. 1998. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J. Exp. Med. 187:1193-1204.
34. Carpenter, P.A., et al. 2000. Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressivein vivo. Transplant Proc. 32:1545-1546.
35. Carpenter, P.A., et al. 2000. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165:6205-6213.
36. Wesselborg, S., Janssen, O., and Kabelitz, D. 1993. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 150:4338-4345.
37. Janssen, O., Wesselborg, S., and Kabelitz, D. 1992. Immunosuppression by OKT3 - induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation. 53:233-234.
38. Chau, LA., Bluestone, J.A., and Madrenas, J. 1998. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell recepror. J. Exp. Med. 187:1699-1709.
39. Carpenter, P.A., et al. 2002. A humanized non-FcR-binding anti-CD3 antibody, visilizu mab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 99:2712-2719.
40. Hetold, K.C., et al. 1996 Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J. Immunol. 156:3521-3527.
41. Katz, J.D., Benoist, C., and Mathis, D. 1995. T helper cell subsets in insulin-dependent diabetes. Science. 268:1185-1188.
42. Wang, B., et al. 1997. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc. Natl. Acad. Sci. USA. 94:13844-13849.
43. Zipris, D., et al. 1996. Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. J. Immunol. 156:1315-1321.
44. Rabinovitch, A. 1998. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 14:129-151.
45. Mosmann, T.R., and Moore, K.W. 1991. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol. Today. 12:A49-A53.
46. de Waal Malefyt, R., et al. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209-1220.
47. Moore, K.W., et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765.
48. Pakala, S.V., Kurrer, M.O., and Katz, J.D. 1997. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J. Exp. Med. 186:299-306.
49. Serreze, D.V., et al. 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166:1352-1359.
50. D'Ambrosio, D., et al. 1998. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J. Immunol. 161:5111-5115.
51. Groux, H., et al. 1996. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 184:19-29.
52. Roncarolo, M.G., et al. 2001. Type 1 T regulatory cells. Immunol. Rev. 182:68-79.
53. Moritani, M., et al. 1996. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes. J. Clin. Invest. 98:1851-1859.
54. Zheng, X.X., et al. 1997. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J. Immunol. 158:4507-4513.
55. Sebastiani, S., et al. 2001. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J. Immunol. 166:996-1002.
56. Iellem, A. 2001. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194:847-853.
57. Dieckmann, D., et al. 2002. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 1-producing, contact-independent type 1-like regulatory T cells. J. Exp. Med. 196:247-253.
58. Annunziato, F., et al. 2002. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J. Exp. Med. 196:379-387.
59. Piccirillo, C.A., et al. 2002. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J. Exp. Med. 196:237-246.
60. Levings, M.K., Sangregorio, R., and Roncarolo, M.G. 2001. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of funcrion. J. Exp. Med. 193:1295-1302.